Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; polysorbate 80; crospovidone; purified talc; macrogol 6000; magnesium stearate; povidone; colloidal anhydrous silica; hypromellose - the treatment of chronic cholestatic liver diseases

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: maize starch; colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; titanium dioxide; gelatin; sodium lauryl sulfate; sorbitan monolaurate - ursosan is indicated in the treatment of chronic cholestatic liver diseases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; titanium dioxide; maize starch; gelatin; sodium lauryl sulfate; magnesium stearate; purified water - the treatment of chronic cholestatic liver diseases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; purified water; maize starch; titanium dioxide; magnesium stearate; gelatin; colloidal anhydrous silica - the treatment of chronic cholestatic liver diseases.

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

leadiant gmbh - l'acide chénodésoxycholique - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile et la thérapie du foie - l’acide chénodésoxycholique est indiqué pour le traitement des erreurs innées de la synthèse des acides biliaires primaires carence stérol 27 hydroxylase (présentant comme xanthomatose cérébrotendineuse (ctx)) chez les nourrissons, enfants et adolescents âgés de 1 mois à 18 ans et adultes.

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic ácido - xanthomatosis, cerebrotendinous; metabolism, inborn errors - terapia bilis e hepática - o ácido chenodeoxicólico é indicado para o tratamento de erros inatos da síntese de ácido biliar primário devido à deficiência de esterol 27 hidroxilase (apresentando como xantomatose cerebroendinosa (ctx)) em lactentes, crianças e adolescentes de 1 mês a 18 anos e adultos.

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - ursodeoxycholic acid - oral tablet - 150mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ursodeoxycholic acid - oral tablet - 300mg

Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic sýru - xanthomatosis, cerebrotendinous; metabolism, inborn errors - galla og lifrarmeðferð - chenodeoxycholic sýru er ætlað fyrir meðferð meðfæddan villur af aðal galli sýru myndun vegna steról 27 hýdroxýlkljúfs skort (kynna eins og cerebrotendinous xanthomatosis (ctx)) í börn, börn og unglingar á aldrinum 1 mánuð til 18 ára og fullorðnir.

Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic syre - xanthomatosis, cerebrotendinous; metabolism, inborn errors - galle- og leverterapi - chenodeoxycholic syre er indisert for behandling av medfødte feil av primære gallesyre syntese på grunn av sterol 27 hydroksylase mangel (presentere som cerebrotendinous xanthomatosis (ctx)) i spedbarn, barn og unge i alderen 1 måned til 18 år og voksne.